title: [Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].
abstract: Our objective has been to elaborate an updated Clinical Guide of the Spanish Society of Internal Medicine (SEMI) for the prevention and treatment of glucocorticoids-induced osteoporosis (GIO), identifying and measuring the grade of evidence that supports the given recommendations. For this, we reviewed studies performed on pathophysiology, diagnosis, prevention and treatment of GIO and after analyzing them we elaborated the present recommendations. This was done after a pre-specified and reproducible process that included an accepted model for the evaluation, and the reference of the evidence that supported it. Once the Scientific Committee elaborated the draft of the Clinical Guide, it was reviewed by all the members of the Working Group on Osteoporosis of the SEMI, and by an External Committee who included experts of many different specialities. Pathophysiology of GIO is complex and yet unknown. Bone effects of glucocorticoids are determined by multiple factors although accumulated doses seems to be the most important one. The best method to diagnose GIO is Dual X-Ray Absorptiometry (DXA), although WHO criteria defined for the diagnosis of postmenopausal osteoporosis are not applicable in GIO. The presence of a T-score lower than -1.5 Tscore indicates the necessity of treatment in any patient who receives or is going to receive more than 3 months treatment with glucocorticoids at a dose higher than 2.5 mg/day (in postmenopausal women) and 5 mg/day (in premenopausal women and men). DXA is also useful to follow up the patients, who can be done annually. Treatment must be prescribed to any patient who is receiving glucocorticoids or is going to receive them at doses higher than 7.5 mg/day for more than 3 months and 5 mg/day if the patient is a postmenopausal woman or has suffered from previous fragility fractures. Risedronate and alendronate are the drugs of election, always together with calcium and vitamin D supplements and general measurements usually prescribed in the treatment of osteoporosis. In very ill patients, parathyroid hormone can be used. The treatment for GIO should be maintained while glucocorticoid therapy is used.
authors.affiliation: Grupo de Trabajo en Osteoporosis de la Sociedad Española de Medicina Interna, Spain. manuelsosah@canariastelecom.com
authors.forename: M
authors.initials: M
authors.lastname: Sosa Henríquez
authors.forename: M
authors.initials: M
authors.lastname: Díaz Curiel
authors.forename: A
authors.initials: A
authors.lastname: Díez Pérez
authors.forename: C
authors.initials: C
authors.lastname: Gómez Alonso
authors.forename: J
authors.initials: J
authors.lastname: González Macías
authors.forename: J
authors.initials: J
authors.lastname: Farrerons Minguella
authors.forename: J
authors.initials: J
authors.lastname: Filgueira Rubio
authors.forename: L
authors.initials: L
authors.lastname: Mellibovsky Saidler
authors.forename: X
authors.initials: X
authors.lastname: Nogués Solán
authors.forename: D
authors.initials: D
authors.lastname: Hernández Hernández
mesh_terms: D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D000068296:Risedronic Acid
chemical_list: D005938:Glucocorticoids; D000068296:Risedronic Acid; D012968:Etidronic Acid